Page last updated: 2024-09-03

candoxatril and substance p

candoxatril has been researched along with substance p in 2 studies

Compound Research Comparison

Studies (candoxatril)	Trials (candoxatril)	Recent Studies (post-2010) (candoxatril)	Studies (substance p)	Trials (substance p)	Recent Studies (post-2010) (substance p)
62	29	5	17,289	277	2,010

Protein Interaction Comparison

Protein	Taxonomy	substance p (IC50)
Substance-P receptor	Rattus norvegicus (Norway rat)	0.0005
Substance-K receptor	Rattus norvegicus (Norway rat)	0.2
Substance-K receptor	Homo sapiens (human)	0.2455
Substance-P receptor	Homo sapiens (human)	0.0011
Neuromedin-K receptor	Homo sapiens (human)	0.125
Substance-K receptor	Mesocricetus auratus (golden hamster)	0.148

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Doi, H; Kugiyama, K; Matsumura, T; Ohta, Y; Sugiyama, S; Yasue, H	1
Arnal, JF; Bayard, F; Castano, C; Darblade, B; Gourdy, P; Maupas, E; Michel, JB; Mugniot, A	1

Other Studies

2 other study(ies) available for candoxatril and substance p

Article	Year
Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Arteriosclerosis, thrombosis, and vascular biology, 1996, Volume: 16, Issue:8 Topics: Administration, Oral; Animals; Aorta, Thoracic; Arteriosclerosis; Atrial Natriuretic Factor; Body Weight; Cholesterol, Dietary; Diet, Atherogenic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycopeptides; Hemodynamics; Hypercholesterolemia; Indans; Lipids; Male; Natriuretic Peptide, C-Type; Neprilysin; Nitroprusside; Organ Culture Techniques; Propionates; Proteins; Rabbits; Substance P; Vasodilation	1996
Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis, 2001, Volume: 155, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Arteriosclerosis; Atrial Natriuretic Factor; Body Weight; Bradykinin; Cholesterol; Cholesterol, HDL; Drug Evaluation, Preclinical; Indans; Male; Mice; Mice, Knockout; Neprilysin; Propionates; Protease Inhibitors; Pyridines; Substance P; Thiazepines; Triglycerides	2001

Article

Year

Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).

Arteriosclerosis, thrombosis, and vascular biology, 1996, Volume: 16, Issue:8

Topics: Administration, Oral; Animals; Aorta, Thoracic; Arteriosclerosis; Atrial Natriuretic Factor; Body Weight; Cholesterol, Dietary; Diet, Atherogenic; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glycopeptides; Hemodynamics; Hypercholesterolemia; Indans; Lipids; Male; Natriuretic Peptide, C-Type; Neprilysin; Nitroprusside; Organ Culture Techniques; Propionates; Proteins; Rabbits; Substance P; Vasodilation

1996

Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.

Atherosclerosis, 2001, Volume: 155, Issue:2

Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Arteriosclerosis; Atrial Natriuretic Factor; Body Weight; Bradykinin; Cholesterol; Cholesterol, HDL; Drug Evaluation, Preclinical; Indans; Male; Mice; Mice, Knockout; Neprilysin; Propionates; Protease Inhibitors; Pyridines; Substance P; Thiazepines; Triglycerides

2001